Wegovy (semaglutide)Novo Nordisk—Semaglutide's patent expires in India and many generic versions launchOral WegovyNovo Nordisk—FDA approves oral Wegovy (semaglutide 25 mg) as first oral GLP-1 for obesityWegovy (semaglutide)Novo Nordisk—FDA approves Wegovy pill, oral semaglutide 25 mg, for weight managementOral WegovyNovo Nordisk—Oral Wegovy surpasses 3 million prescriptions in five months following January 2026 launchNovo Nordisk—Novo Nordisk's US decision on haemophilia drug denecimig slips past third quarter 2026
Amycretin
Amycretin is a GLP-1 receptor and amylin agonist dual agonist in development for weight loss. Phase 1b/2a showed 22% weight loss.
PilotStage 3 of 5
Phase 3; next-generation dual agonist showing 22% weight loss with weekly injection.
Updated 24 Jan 2025Checked 10 Oct0 updates this week